Table 2 Patient demographic and baseline characteristics (N = 122)
Characteristics | All (N = 122) | SEQ (N = 54) | SIB (N = 68) | p-value |
|---|---|---|---|---|
Age, years | 0.680 | |||
Mean ± SD | 49.39 ± 10.30 | 49.7 ± 10.63 | 48.96 ± 9.96 | |
Sex | 0.563 | |||
Male | 95 (77.9 %) | 39 (72.2 %) | 56 (82.4 %) | |
Female | 27 (22.1 %) | 15 (27.8 %) | 12 (17.6 %) | |
Performance status | - | |||
90–100 | 122 (100 %) | 54 (100 %) | 68 (100 %) | |
WHO classification | 0.983 | |||
Type I (Keratinizing SCCA) | 2 (1.6 %) | 1 (1.9 %) | 1 (1.5 %) | |
Type IIA (NK, diff. SCCA) | 11 (9.0 %) | 5 (9.2 %) | 6 (8.8 %) | |
Type IIB (NK,undiff. SCCA) | 109 (89.4 %) | 48 (88.9 %) | 61 (89.7 %) | |
T stage | 0.741 | |||
1 | 35 (28.7 %) | 17 (31.5 %) | 18 (26.5 %) | |
2 | 50 (41.0 %) | 22 (40.7 %) | 28 (41.2 %) | |
3 | 24 (19.7 %) | 11 (20.4 %) | 13 (19.1 %) | |
4 | 13 (10.6 %) | 4 (7.4 %) | 9 (13.2 %) | |
N stage | 0.910 | |||
0 | 5 (4.1 %) | 2 (3.7 %) | 3 (4.4 %) | |
1 | 22 (18.0 %) | 9 (16.6 %) | 13 (19.1 %) | |
2 | 77 (63.2 %) | 36 (66.7 %) | 41 (60.3 %) | |
3 | 18 (13.8 %) | 7 (13.0 %) | 11 (16.2 %) | |
AJCC Stage grouping | 0.259 | |||
II | 18 (14.8 %) | 8 (14.8 %) | 10 (14.7 %) | |
III | 75 (61.4 %) | 37 (68.5 %) | 38 (55.9 %) | |
IVA | 11 (9.0 %) | 2 (3.7 %) | 9 (13.2 %) | |
IVB | 18 (14.8 %) | 7 (13.0 %) | 11 (16.2 %) | |
Mean PTV volume, cc | 0.432 | |||
PTV-HR ± SD | 366.29 ± 122.07 | 354.76 ± 105.61 | 376.68 ± 135.70 | |
PTV-LR ± SD | 813.7 ± 150.52 | 802.98 ± 146.84 | 823.37 ± 154.98 | 0.558 |
RT duration, days | 0.002 | |||
Mean ± SD | 49.36 ± 3.72 | 50.54 ± 3.87 | 48.43 ± 3.33 |